Aclaris Therapeutics, Inc. (ACRS) Income Statement Analysis

See more : Rochester Community Baseball Inc. (RCCB) Income Statement Analysis – Financial Results

Complete financial analysis of Aclaris Therapeutics, Inc. (ACRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aclaris Therapeutics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Coliseum Acquisition Corp. (MITA) Income Statement Analysis – Financial Results
DB Insurance Co., Ltd. (005830.KS) Income Statement Analysis – Financial Results
Binero Group AB (publ) (BINERO.ST) Income Statement Analysis – Financial Results
Nagreeka Capital & Infrastructure Ltd. (NAGREEKCAP.BO) Income Statement Analysis – Financial Results
Disruptive Acquisition Corporation I (DISAU) Income Statement Analysis – Financial Results

Aclaris Therapeutics, Inc. (ACRS)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.aclaristx.com

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	31.25M	29.75M	6.76M	6.48M	4.23M	10.09M	1.68M	0.00	0.00	0.00	0.00
Cost of Revenue	18.08M	11.96M	4.71M	5.13M	4.06M	6.85M	1.21M	120.00K	90.00K	0.00	0.00
Gross Profit	13.17M	17.79M	2.05M	1.35M	172.00K	3.24M	476.00K	-120.00K	-90.00K	0.00	0.00
Gross Profit Ratio	42.14%	59.80%	30.29%	20.81%	4.07%	32.12%	28.28%	0.00%	0.00%	0.00%	0.00%
Research & Development	98.38M	77.81M	43.81M	31.73M	64.90M	63.01M	39.79M	33.48M	15.34M	6.51M	3.49M
General & Administrative	31.10M	25.13M	23.62M	20.53M	27.16M	27.65M	33.11M	15.09M	5.33M	2.03M	1.77M
Selling & Marketing	0.00	0.00	0.00	283.00K	671.00K	48.00M	85.00K	3.30M	0.00	0.00	0.00
SG&A	31.10M	25.13M	23.62M	20.53M	27.83M	75.65M	33.11M	15.09M	5.33M	2.03M	1.77M
Other Expenses	0.00	2.95M	-1.14M	-424.00K	-2.48M	2.68M	2.07M	488.00K	0.00	0.00	0.00
Operating Expenses	130.80M	102.95M	67.43M	52.26M	92.73M	138.66M	72.90M	48.57M	20.67M	8.53M	5.26M
Cost & Expenses	128.61M	114.91M	72.15M	57.39M	96.78M	145.51M	74.11M	48.57M	20.67M	8.53M	5.26M
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	104.00K	16.00K	21.00K
Interest Expense	0.00	4.70M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	863.00K	797.00K	923.00K	1.32M	1.59M	1.32M	402.00K	120.00K	90.00K	12.00K	11.00K
EBITDA	-117.57M	-84.36M	-65.06M	-48.20M	-90.84M	-80.78M	-53.45M	-48.57M	-20.67M	-8.52M	-5.25M
EBITDA Ratio	-376.22%	-267.74%	-607.08%	-785.44%	-1,751.83%	-1,341.93%	-4,303.21%	0.00%	0.00%	0.00%	0.00%
Operating Income	-97.36M	-85.15M	-65.38M	-50.91M	-111.06M	-135.41M	-72.42M	-48.57M	-20.67M	-8.53M	-5.26M
Operating Income Ratio	-311.55%	-286.21%	-967.08%	-785.44%	-2,627.35%	-1,341.93%	-4,303.21%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	8.51M	2.95M	-1.14M	-424.00K	-2.48M	2.68M	-15.99M	488.00K	104.00K	16.00K	21.00K
Income Before Tax	-88.85M	-86.91M	-90.87M	-51.34M	-113.54M	-132.74M	-70.35M	-48.08M	-20.56M	-8.52M	-5.24M
Income Before Tax Ratio	-284.32%	-292.11%	-1,343.96%	-791.98%	-2,686.11%	-1,315.41%	-4,180.21%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-367.00K	1.75M	23.42M	-182.00K	29.31M	2.68M	-1.83M	-120.00K	-90.00K	0.00	0.00
Net Income	-88.48M	-88.66M	-114.28M	-51.15M	-142.85M	-132.74M	-68.52M	-48.08M	-20.56M	-8.52M	-5.24M
Net Income Ratio	-283.15%	-298.00%	-1,690.30%	-789.17%	-3,379.47%	-1,315.41%	-4,071.48%	0.00%	0.00%	0.00%	0.00%
EPS	-1.27	-1.36	-2.01	-1.20	-3.46	-4.03	-2.44	-2.25	-3.37	-0.80	-0.49
EPS Diluted	-1.27	-1.36	-2.01	-1.20	-3.46	-4.03	-2.44	-2.25	-3.37	-0.80	-0.49
Weighted Avg Shares Out	69.81M	65.21M	56.73M	42.54M	41.32M	32.91M	28.10M	21.42M	6.11M	10.66M	10.66M
Weighted Avg Shares Out (Dil)	69.81M	65.21M	56.73M	42.54M	41.32M	32.91M	28.10M	21.42M	6.11M	10.66M	10.66M

Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)

November 16, 2023zacks.com

Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study

November 14, 2023zacks.com

Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.

Aclaris Therapeutics pulls arthritis drug research program; shares plummet

November 13, 2023proactiveinvestors.com

Aclaris Therapeutics shares fell almost 90% after the biopharmaceutical company announced it is no longer continuing with the development of its rheumatoid arthritis therapeutic zunsemetinib. The company said that its Phase 2b study of zunsemetinib did not meet its primary...

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

November 13, 2023reuters.com

Aclaris Therapeutics on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial.

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

November 13, 2023globenewswire.com

— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET — WAYNE, Pa., Nov. 13,...

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

November 6, 2023globenewswire.com

- Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Topline Data Anticipated Around Year-End 2023 - WAYNE, Pa., Nov....

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

October 3, 2023globenewswire.com

- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into...

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

September 28, 2023seekingalpha.com

Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps advance small molecules targeting kinases to replicate or improve the effects of expensive biologics. ACRS has a lead asset, zunsemetinib, in phase...

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

September 20, 2023globenewswire.com

WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside...